Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, emerging research suggests that vaccines can meaningfully reduce the risk of dementia-related complications and cognitive decline. Multiple studies published over the past few years have found associations between various vaccinations—particularly influenza, shingles, and pneumococcal vaccines—and lower rates of Alzheimer’s disease and other forms of dementia in older adults. For example, a groundbreaking study published in *Neurology* in April 2026 found that older adults who received a high-dose influenza vaccine showed approximately 55% lower risk of developing Alzheimer’s disease over a roughly two-year period, suggesting that even vaccines developed for other purposes may offer neurological benefits.
The protective effects appear to work across multiple vaccine types and populations. A comprehensive meta-analysis examining approximately 2.09 million adults found that those who received standard-dose influenza vaccination had a 31% lower risk of incident dementia, while other research has documented protective effects from shingles vaccination, RSV vaccines, pneumococcal vaccines, and even COVID-19 vaccination in those already experiencing cognitive decline. While these findings don’t prove that vaccines directly prevent dementia, they suggest a potentially important avenue for reducing one of the most serious health threats facing older adults.
Table of Contents
- How Do Vaccines Protect Against Dementia Risk?
- Evidence from Major Studies and Important Limitations
- Comparing Protection Across Different Vaccines
- What Older Adults With Cognitive Concerns Should Know
- Important Caveats and Why Longer-Term Data Still Matters
- The Infection Prevention Connection
- Looking Ahead: Vaccine Development and Dementia Prevention
- Conclusion
How Do Vaccines Protect Against Dementia Risk?
The biological mechanisms behind vaccine-related dementia risk reduction are still being studied, but researchers have identified several plausible explanations. Vaccinations may reduce dementia risk by preventing infections that would otherwise cause inflammation in the brain—a process increasingly recognized as a driver of cognitive decline and neurodegeneration. Influenza, in particular, triggers systemic inflammation that can cross the blood-brain barrier, potentially damaging neurons and accelerating the development of amyloid plaques and tau tangles characteristic of Alzheimer’s disease. When vaccines prevent these infections, they may be preventing these inflammatory cascades.
Beyond infection prevention, vaccines appear to trigger broader immune system modulation effects that have neuroprotective consequences. Research from Oxford University analyzing the available evidence suggests that vaccination may decrease what researchers call “vascular and neuroinflammatory assaults”—the accumulated cellular damage from infections, inflammation, and age-related vascular changes that promote cognitive decline. This is not specific to dementia prevention; it reflects how the immune system’s response to vaccination seems to create a more balanced, less inflammatory state throughout the body, including in neural tissues. The protection appears robust enough that it extends across multiple vaccine types, suggesting the mechanism is not specific to any single antigen but rather relates to the general strengthening and modulation of immune function.

Evidence from Major Studies and Important Limitations
The strongest evidence comes from vaccines that have been used for decades with long-term follow-up data. Standard influenza vaccination in older adults is associated with a 40% reduced risk of Alzheimer’s disease in matched US cohorts, a finding replicated across nine different studies involving 292,157 older participants. The high-dose flu vaccine—formulated with four times the standard antigen load for older adults—showed even stronger protection in recent research. Similarly, shingles vaccination, particularly the newer Shingrix formulation, has demonstrated convincing reductions in dementia risk compared to the older Zostavax vaccine, suggesting that vaccine technology improvements may enhance neuroprotective benefits. However, it is important to recognize a crucial limitation: these findings come from observational studies, not randomized controlled trials, and are classified as Class II evidence.
This means they demonstrate associations between vaccination and lower dementia risk, but they cannot definitively prove that vaccines cause dementia risk reduction. People who get vaccinated tend to have higher overall health engagement, better access to healthcare, higher socioeconomic status, and other factors that independently correlate with better health outcomes. While researchers use statistical matching to account for these confounding factors, some uncertainty remains. Additionally, for newer vaccines like COVID-19 vaccines, only a few years of data exist, so longer-term effects remain unknown. The evidence is encouraging, but not yet conclusive.
Comparing Protection Across Different Vaccines
Different vaccines show varying degrees of apparent protection. Pneumococcal vaccination—which prevents bacterial pneumonia—is associated with 25-40% risk reduction of dementia across multiple studies, making it one of the more studied protective vaccines. The DTP vaccine (diphtheria, tetanus, pertussis) has also shown associations with reduced dementia risk, though with less robust supporting evidence than influenza or shingles vaccines. The RSV vaccine (Arexvy), newly available for older adults to prevent respiratory syncytial virus infection, is linked to significantly lower dementia risk, though because it is so new, the body of evidence remains smaller. The high-dose influenza vaccine represents a notable advance over standard-dose influenza vaccination in terms of apparent protection.
The 55% risk reduction found in the 2026 *Neurology* study exceeds the approximately 40% reduction associated with standard-dose flu shots. This suggests that a higher immune challenge—more antigen—may produce greater neuroprotective effects. However, high-dose flu vaccine can also cause more injection-site reactions and mild systemic symptoms. Some older adults experience more arm soreness, fatigue, or low-grade fever than with standard-dose vaccine, a tradeoff worth considering when discussing vaccine choice with a healthcare provider. For those able to tolerate it, the enhanced protection may justify these temporary side effects.

What Older Adults With Cognitive Concerns Should Know
For people already experiencing cognitive decline, the stakes of vaccination may be even higher. Research examining older adults with existing cognitive disorders found that those vaccinated against COVID-19 showed 1.2 fewer points of annual decline on the MMSE (Mini-Mental State Examination), a standard cognitive test—a subtle difference that, compounded over years, translates into meaningfully slower disease progression. On the ADAS-Cog scale (Alzheimer’s Disease Assessment Scale), vaccinated individuals showed approximately 30% slower cognitive decline compared to unvaccinated peers. These findings came from analysis of 65,544 older adults without cognitive disorders and 25,733 with cognitive disorders, assessed between March 2020 and February 2022.
This suggests that vaccination may be valuable not only for prevention in cognitively normal older adults, but also for slowing decline in those already experiencing mild cognitive impairment or dementia. The practical implication is significant: vaccination becomes both a preventive intervention for those concerned about future risk and a potentially disease-modifying approach for those already showing signs of cognitive decline. Current guidelines recommend that all older adults maintain up-to-date vaccinations regardless of baseline cognitive status, particularly influenza, pneumococcal, shingles, and now RSV vaccines when eligible. A conversation with a healthcare provider about vaccine selection and timing can help optimize benefits while minimizing any temporary side effects.
Important Caveats and Why Longer-Term Data Still Matters
One critical limitation is that most robust evidence exists for vaccines introduced decades ago. The influenza vaccine has been used since the 1940s, and long-term epidemiological data spanning decades allows researchers to draw conclusions about dementia risk across entire lifespans. The shingles vaccine became available in 1985 (as Zostavax) and 2017 (as Shingrix). COVID-19 vaccines entered widespread use in 2021, meaning we have perhaps five years of follow-up data for the oldest vaccinated cohorts. In aging research, this is a relatively short timeframe. Some effects—protective or harmful—might only become apparent with ten, twenty, or more years of observation.
The appearance of protective effects with COVID-19 vaccination is encouraging, but longer follow-up studies are essential before drawing firm conclusions about long-term neuroprotection. Another important caveat involves study design. Because randomized controlled trials specifically testing whether vaccines prevent dementia would be unethical (researchers cannot randomize people to avoid vaccination for years) and impractical (dementia develops over decades), all the evidence comes from observational studies that compare vaccinated and unvaccinated people. These studies use statistical techniques to match people on age, sex, education, comorbidities, and other factors, but unmeasured differences may remain. For instance, people willing to get vaccinated during a pandemic might differ in unmeasured ways from those reluctant to vaccinate. Researchers work to minimize these biases, but they cannot be entirely eliminated. This is why the evidence is considered suggestive and encouraging rather than definitive.

The Infection Prevention Connection
Understanding why infection prevention matters for dementia risk requires recognizing that infections in older age are not trivial events. Influenza is associated with 12,000 to 52,000 excess deaths annually in the US, but beyond mortality, infection survivors often experience worsening of chronic conditions and accelerated cognitive decline. After severe influenza or pneumonia, some older adults never fully recover cognitively, suggesting that the systemic inflammation and physiological stress of severe infection causes lasting neural damage. Vaccination prevents not only the immediate illness but also this downstream cognitive consequence.
The example of herpes zoster (shingles) illustrates this particularly well. Shingles is not typically life-threatening, but it causes intense pain, disrupts sleep, and triggers substantial systemic inflammation. Studies show that in the months and years following shingles infection, individuals experience higher dementia risk compared to those who never had shingles. The Shingrix vaccine, by preventing shingles infection entirely, may eliminate this risk. This has led some researchers to propose that aggressive infection prevention through vaccination might be one of the most underutilized tools for maintaining cognitive health in older adults.
Looking Ahead: Vaccine Development and Dementia Prevention
The dementia-protective effects of existing vaccines have prompted researchers to consider whether future vaccines might be developed specifically to reduce dementia risk. Some scientists are exploring vaccines targeting amyloid-beta or tau proteins directly, aiming to prevent or slow Alzheimer’s disease pathology. Others are examining whether broader immune-training vaccines—designed to enhance overall immune competence—might confer both infection prevention and neuroprotection. The discovery that existing vaccines for infection prevention also appear to protect cognitive function suggests that immune system health and neurological health are more closely connected than previously appreciated.
This emerging understanding may reshape vaccination recommendations for older adults in coming years. Rather than viewing vaccines narrowly as tools to prevent specific infectious diseases, healthcare providers increasingly see them as part of a broader cognitive health strategy. As research continues and longer-term data accumulates for COVID-19 vaccines and newer formulations, recommendations may strengthen. The combination of vaccination, cognitive stimulation, cardiovascular fitness, social engagement, and sleep management may represent the most evidence-based approach to dementia prevention currently available to older adults.
Conclusion
The evidence, while still emerging and based on observational studies rather than definitive proof, suggests that vaccines—particularly flu, shingles, pneumococcal, and RSV vaccines—can reduce the risk of developing dementia and slow cognitive decline in those already experiencing it. The apparent protection is substantial enough (ranging from 25% to 55% risk reduction depending on the vaccine) to be clinically meaningful, especially when considering that dementia has no cure and prevention is our most effective strategy. The biological plausibility—that vaccines reduce brain-damaging infections and inflammation—provides a reasonable mechanistic explanation for these associations.
If you are an older adult or the family member of one, discussing current vaccination status with your healthcare provider is an important step in a comprehensive approach to brain health. Keeping influenza, pneumococcal, shingles, and RSV vaccinations current may offer dual benefits: protection against serious infectious diseases and reduced dementia risk. While longer-term data, particularly for newer vaccines, will ultimately provide more definitive answers, the current evidence supports vaccination as part of standard dementia prevention practice for all older adults.
You Might Also Like
- Can Parkinson’s-Related Smell Loss Predict Cognitive Decline?
- Can Online Grocery Apps Help Dementia Families?
- Can Nightmares Become More Common With Dementia?
For more, see Alzheimer’s Association — caregiving.





